We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

74 hedge funds and large institutions have $104M invested in Stemline Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 30 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $690K | Put options by funds: $344K

100% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 15

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

8% more capital invested

Capital invested by funds: $96.2M → $104M (+$7.96M)

7% more funds holding

Funds holding: 69 → 74 (+5)

Holders
74
Holders Change
+5
Holders Change %
+7.25%
% of All Funds
1.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
30
Reduced
15
Closed
8
Calls
$690K
Puts
$344K
Net Calls
+$346K
Net Calls Change
+$264K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$3.14M
2
FCM
Farallon Capital Management
California
+$3.11M
3
JGC
J. Goldman & Co
New York
+$2.42M
4
Millennium Management
Millennium Management
New York
+$1.38M
5
BIM
Bogle Investment Management
Massachusetts
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.67M
2
Franklin Resources
Franklin Resources
California
-$2.34M
3
RA
Royce & Associates
New York
-$852K
4
CCI
Columbus Circle Investors
-$580K
5
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
-$400K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$701K +$58.1K +4,800 +8%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$685K +$173K +14,281 +29%
CLOS
28
Compagnie Lombard Odier SCmA
Switzerland
$647K – – –
Acadian Asset Management
29
Acadian Asset Management
Massachusetts
$640K +$276K +22,827 +62%
PAM
30
Panagora Asset Management
Massachusetts
$594K +$671K +55,506 New
TCIM
31
TIAA CREF Investment Management
New York
$581K -$126K -10,457 -16%
Morgan Stanley
32
Morgan Stanley
New York
$533K +$565K +46,697 +1,514%
Ameriprise
33
Ameriprise
Minnesota
$433K +$489K +40,400 New
OAM
34
Oxford Asset Management
United Kingdom
$431K +$487K +40,298 New
TA
35
Teachers Advisors
New York
$377K +$100K +8,282 +31%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$372K -$10.9K -900 -3%
ORI
37
Oak Ridge Investments
Illinois
$365K +$258K +21,357 +167%
SIP
38
Stoneridge Investment Partners
Pennsylvania
$361K – – –
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$334K – – –
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$334K +$31.6K +2,611 +9%
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$333K – – –
Charles Schwab
42
Charles Schwab
California
$279K – – –
CD
43
Carl Domino
Florida
$278K – – –
JP Morgan Chase
44
JP Morgan Chase
New York
$269K +$274K +22,632 +909%
TI
45
Telemetry Investments
New York
$268K +$24.4K +2,016 +9%
Jacobs Levy Equity Management
46
Jacobs Levy Equity Management
New Jersey
$267K -$318K -26,289 -51%
PAM
47
Paradigm Asset Management
New York
$244K -$8.47K -700 -3%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$206K -$71.1K -5,876 -23%
Wells Fargo
49
Wells Fargo
California
$140K +$64.3K +5,313 +68%
LTFS
50
Ladenburg Thalmann Financial Services
Florida
$136K +$137K +11,300 +811%
1
2
3 4

STML Hedge Fund Activity: Q4 2016 in Review

74 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2016, worth a combined $104M — up 8.3% from $96.2M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new STML positions and 8 closed out — a net gain of 5 holders — while 30 added to existing stakes and 15 trimmed.

The largest buyer was Sabby Management, adding an estimated $3.14M. The largest seller was Fidelity Investments, cutting an estimated $4.67M.

  • 74 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2016, up from 69 in Q3 2016.
  • Funds reported $104M of Stemline Therapeutics, Inc. stock for Q4 2016, up 8.3% quarter-over-quarter.
  • 13 funds opened new Stemline Therapeutics, Inc. positions in Q4 2016 and 8 closed out, a net change of +5 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q4 2016 was Sabby Management, an estimated $3.14M added.
  • The largest Stemline Therapeutics, Inc. seller in Q4 2016 was Fidelity Investments, an estimated $4.67M sold.

Based on aggregated 13F filings for Q4 2016.